Literature DB >> 18794076

The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).

Richard L Schilsky1, Gary Gordon, Tona M Gilmer, Sara A Courtneidge, Lynn M Matrisian, Oren Grad, William G Nelson.   

Abstract

The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the National Cancer Institute's investment in translational research and envision its future. The TRWG conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of agents-both small molecules and biologics-for the treatment and prevention of cancer. The Agents Developmental Pathway was conceived not as a comprehensive description of the corresponding real-world processes, but rather as a tool designed to facilitate movement of an agent through the translational process to the point where it can begin definitive clinical testing. This article presents the Agents Developmental Pathway and discusses key challenges associated with the processes described.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18794076      PMCID: PMC3978169          DOI: 10.1158/1078-0432.CCR-08-1265

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  36 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

3.  Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

Authors:  Hagop Kantarjian; Charles Sawyers; Andreas Hochhaus; Francois Guilhot; Charles Schiffer; Carlo Gambacorti-Passerini; Dietger Niederwieser; Debra Resta; Renaud Capdeville; Ulrike Zoellner; Moshe Talpaz; Brian Druker; John Goldman; Stephen G O'Brien; Nigel Russell; Thomas Fischer; Oliver Ottmann; Pascale Cony-Makhoul; Thierry Facon; Richard Stone; Carole Miller; Martin Tallman; Randy Brown; Michael Schuster; Thomas Loughran; Alois Gratwohl; Franco Mandelli; Giuseppe Saglio; Mario Lazzarino; Domenico Russo; Michele Baccarani; Enrica Morra
Journal:  N Engl J Med       Date:  2002-02-28       Impact factor: 91.245

4.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

5.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

Authors:  William Pao; Vincent Miller; Maureen Zakowski; Jennifer Doherty; Katerina Politi; Inderpal Sarkaria; Bhuvanesh Singh; Robert Heelan; Valerie Rusch; Lucinda Fulton; Elaine Mardis; Doris Kupfer; Richard Wilson; Mark Kris; Harold Varmus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

6.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Authors:  Richard LeBlanc; Laurence P Catley; Teru Hideshima; Suzanne Lentzsch; Constantine S Mitsiades; Nicholas Mitsiades; Donna Neuberg; Olga Goloubeva; Christine S Pien; Julian Adams; Deepak Gupta; Paul G Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2002-09-01       Impact factor: 12.701

Review 7.  Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer.

Authors:  Julian Adams
Journal:  Curr Opin Chem Biol       Date:  2002-08       Impact factor: 8.822

8.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

9.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

10.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Authors:  Leonard B Saltz; Neal J Meropol; Patrick J Loehrer; Michael N Needle; Justin Kopit; Robert J Mayer
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

View more
  3 in total

Review 1.  Translational spinal cord injury research: preclinical guidelines and challenges.

Authors:  Paul J Reier; Michael A Lane; Edward D Hall; Y D Teng; Dena R Howland
Journal:  Handb Clin Neurol       Date:  2012

2.  Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.

Authors:  Shining Wang; Qingyu Zhou; James M Gallo
Journal:  Mol Cancer Ther       Date:  2009-06-09       Impact factor: 6.261

3.  Found in translation: Integrating laboratory and clinical oncology research.

Authors:  H Wagner
Journal:  Biomed Imaging Interv J       Date:  2008-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.